Stifel Maintains Buy on DarioHealth, Lowers Price Target to $6
Portfolio Pulse from jenniferd'souza@benzinga.com
Stifel analyst David Grossman has maintained a 'Buy' rating on DarioHealth (NASDAQ:DRIO) but lowered the price target from $9 to $6.
July 25, 2023 | 11:28 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Stifel analyst maintains a 'Buy' rating on DarioHealth but lowers the price target from $9 to $6.
The news is directly related to DarioHealth. While the 'Buy' rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100